Cancer biobank study aims to unlock secrets of immunotherapy resistance

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort A (GE Cohort) For this study, a maximum of 40 evaluable patients with gastroesophageal adenocarcinoma and 20 patients with squamous cell carcinoma who will receive anti-PD-1 treatment as standard of care treatment will be enrolled (combination therapy regimen with other agents are allowed). Evaluable patients are those that have received at least one dose of anti-PD-1 treatment. 10 patients who are ineligible for immunotherapy will also be enrolled to meet the exploratory objective. Inclusion Criteria: 1. Age \> 18 years 2. Ability to understand and the willingness to sign a written informed consent document 3. Diagnosis of gastric, esophageal, or gastroesophageal junction adenocarcinoma or squamous cell carcinoma. 4. Available archival tumor tissue or willingness to undergo research biopsy. Exclusion Criteria: 1. Patients unable to comply with the requirements of the study protocol 2. Patients known to be pregnant or nursing 3. Serious pre-existing medical condition, that in the opinion of the investigator, makes the patient unsuitable for the study Cohort B (Melanoma Cohort) 1\. All subjects that consented and enrolled to Pro00059349 will be rolled into this protocol for specimen analysis. See Pro00059349 for eligibility criteria for those subjects. Cohort C (Retrospective Cohort) Eligibility Criteria 1. GE subjects must have been treated with an immune checkpoint inhibitor for gastroesophageal adenocarcinoma or squamous cell carcinoma, or have been ineligible for immunotherapy due to low PD-L1 and received chemotherapy. 2. Melanoma subjects in cohort C must have stage II, III, or IV disease validated by histology or cytology 1. Primary cutaneous melanomas or melanomas of unknown primary site are eligible 2. Melanoma subjects must have been treated with immunotherapy (combination with other agents not allowed) 3. Patients with intra-cranial disease or disease involving the central nervous system are eligible.